Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $295.00 at Stifel Nicolaus

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by stock analysts at Stifel Nicolaus from $215.00 to $295.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 21.40% from the company’s previous close.

A number of other research analysts have also recently commented on ALNY. Canaccord Genuity Group restated a “buy” rating and set a $283.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. SVB Leerink raised their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research note on Tuesday. Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Royal Bank of Canada raised their price objective on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $247.09.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $243.00 on Thursday. The firm has a 50-day simple moving average of $159.86 and a 200 day simple moving average of $164.73. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $252.87. The stock has a market cap of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same quarter in the previous year, the business posted ($1.40) EPS. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at approximately $30,013.84. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares of the company’s stock, valued at $1,253,589.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,357 shares of company stock worth $13,436,711. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Quent Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $38,000. Altitude Crest Partners Inc. bought a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $30,000. Finally, GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $52,000. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.